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Background: Although tumor hypoxia poses challenges against conventional cancer treatments, it provides a
therapeutic target for hypoxia-activated drugs. Here, we studied the effect of the hypoxia-activated synthetic
quinoxaline di-N-oxide DCQ against breast cancer metastasis and identified the underlying mechanisms.
Methods: The human breast cancer cell lines MCF-7 (p53 wildtype) and MDA-MB-231 (p53 mutant) were treated
with DCQ under normoxia or hypoxia. Drug toxicity on non-cancerous MCF-10A breast cells was also determined.
In vitro cellular responses were investigated by flow cytometry, transfection, western blotting, ELISA and migration
assays. The anti-metastatic effect of DCQ was validated in the MDA-MB-231 xenograft mouse model.
Results: DCQ selectively induced apoptosis in both human breast cancer cells preferentially under hypoxia without
affecting the viability of non-cancerous MCF-10A. Cancer cell death was associated with an increase in reactive
oxygen species (ROS) independently of p53 and was inhibited by antioxidants. DCQ-induced ROS was associated
with DNA damage, the downregulation of hypoxia inducible factor-1 alpha (HIF-1α), and inhibition of vascular
endothelial growth factor (VEGF) secretion. In MCF-7, HIF-1α inhibition was partially via p53-activation and was
accompanied by a decrease in p-mTOR protein, suggesting interference with HIF-1α translation. In MDA-MB-231,
DCQ reduced HIF-1α through proteasomal-dependent degradation mechanisms. HIF-1α inhibition by DCQ blocked
VEGF secretion and invasion in MCF-7 and led to the inhibition of TWIST in MDA-MB-231. Consistently, DCQ
exhibited robust antitumor activity in MDA-MB-231 breast cancer mouse xenografts, enhanced animal survival,
and reduced metastatic dissemination to lungs and liver.
Conclusion: DCQ is the first hypoxia-activated drug showing anti-metastatic effects against breast cancer,
suggesting its potential use for breast cancer therapy.
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Inadequate oxygen delivery to rapidly growing cancers
forms heterogeneously distributed hypoxic regions within
solid tumors [1,2]. The severity of oxygen deficiency in
such regions is an independent marker of poor prognosis
and is correlated clinically and experimentally with the
resistance of tumors to chemo- and radio-therapies [3].* Correspondence: me00@aub.edu.lb; amro@aub.edu.lb
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reproduction in any medium, provided the orAdditionally, intra-tumoral hypoxia contributes positively
to sequential steps of metastasis and aids in the acquisition
and maintenance of cancer stem cells (CSC) [3-7]. The
master regulator of transcriptional responses to hypoxic
stress is the hetero-dimeric hypoxia induced transcription
factor (HIF). HIF is composed of two subunits, an alpha
subunit (HIF-1α) and a beta subunit (HIF-1β). HIF-1β
subunit is constitutively expressed, while the control of HIF
response is achieved primarily via proteasomal-dependent
degradation of the α subunit [8]. Initially, the degradation
was thought to occur only in an oxygen-dependent
manner; however, several oxygen-independent mechanismsl Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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associated with increased refractiveness of several solid
tumors to conventional therapies [11].
Transcriptional targets of HIF-1α include major regula-
tors of key processes including angiogenesis, epithelial to
mesenchymal transition (EMT), which together lead to me-
tastasis [3,4,11,12]. More recently, HIF-1α was shown to
enhance signaling pathways activated in CSCs, favoring
their enrichment within solid tumors [13,14]. Because hyp-
oxic responses in cancer cells are primarily mediated by
hypoxia inducible factors, targeting HIF-1α directly or
indirectly or eradicating intra-tumoral hypoxic regions are
viable strategies to inhibit aggressive tumors [8,11,15]. Des-
pite such significant challenges posed by tumor hypoxia,
the reductive nature of the hypoxic microenvironment was
exploited for selective activation of several drug classes in-
cluding aromatic N-oxides [11,16]. These drugs undergo re-
duction to produce a transient radical intermediate, which,
in the presence of oxygen, is back oxidized to the non-toxic
pro-drug, hence minimizing side effects to normal non-
hypoxic tissues [16]. The most studied hypoxia-activated
drug is tirapazamine (TPZ). TPZ has reached clinical trials
in combination with other drugs against several cancers;
however, it shows moderate activity against breast cancer,
which is known to bear severely hypoxic regions [17].
We have identified a potent compound that shares the
di-N-oxide moiety with TPZ. This molecule, 2-benzoyl-3-
phenyl-6,7-dichloroquinoxaline 1,4-dioxide (DCQ) inhibits
the viability of several cancer cell lines with a greater
efficacy under hypoxia [18-24]. Additionally, we have
previously shown that DCQ reduces HIF-1α and hypoxia-
induced angiogenesis; however, the mechanism by which
DCQ exerts its effect is still unknown [23]. Hypoxia-acti-
vated drugs can target solid tumors by either killing resistant
cells residing in the hypoxic niche or by modulating hyp-
oxia-induced pathways involved in cancer progression. Here,
we investigated the anti-metastatic activity of DCQ against
breast cancer using two human breast cancer cell lines that
differ in their p53 status, and identified the underlying
mechanisms involved. We show that the antitumor activity
and pro-apoptotic effects of DCQ are selective to cancer
cells and involve the generation of ROS and suppression
of HIF-1α protein expression via different mechanisms in
the two cell lines. The ability of DCQ to inhibit breast
cancer metastasis and HIF-1α expression was validated in
the xenograft model of sub-dermally injected MDA-MB-
231 cells in immune-compromised NOD/SCID mice.
Results and discussion
Results
DCQ selectively reduces cell viability and inhibits colony
formation mostly under hypoxia
Previous studies in our laboratory showed that DCQ
is a potent hypoxic cytotoxin and pro-apoptotic drugin several murine and human cancer cell lines [18-24].
However, its anti-metastatic potential has not been in-
vestigated against human breast cancer, which is known
to harbor severely hypoxic regions [25,26]. MTT assay
showed that DCQ reduced the viability of human breast
cancer MCF-7 and MDA-MB-231 cell lines in a dose- and
time-dependent manner (Figure 1 and data not shown).
The p53 wild type MCF-7 cell line was more resistant
(hypoxia IC50 = 5 μM vs 3 μM in MDA-MB-231) and
hypoxia enhanced drug efficacy in this cell line, while the
aggressive MDA-MB-231 was sensitive under both condi-
tions at 6 hours of exposure (Figure 1A). Interestingly,
DCQ was not toxic to non-cancerous MCF-10A [27]
under normoxic conditions (Additional file 1: Figure S1).
Clonogenic survival assay (Figure 1B) confirmed the
oxygen-dependent cytotoxic activity of DCQ. Treatment
with DCQ (1–10 μM) reduced colony formation more
significantly under hypoxia than normoxia (Figure 1B). In-
creasing the oxygen levels to 10% suppressed the hypoxia-
selectivity of DCQ (Figure 1C). Corresponding to 1% and
10% oxygen, the hypoxia cytotoxicity ratio (HCR) was 3.4
and 1.25 in MCF-7, and 2 and 0.9 in MDA-MB-231,
respectively (Figure 1B and 1C). In accordance with the
cell viability results, clonogenic survival showed that the
invasive MDA-MB-231 was more sensitive, whereby 4 μM
DCQ induced 100% inhibition in colony formation,
however, in MCF-7 this was achieved at 7.5 μM DCQ
(Figure 1B).
To compare DCQ and TPZ activity against human
breast cancer cell lines, we investigated drug effects on
MCF-7 and MDA-MB-231 using trypan blue and MTT
assays. In line with the obtained results, 5 μM DCQ under
hypoxia significantly reduced the viability of MCF-7 and
MDA-MB-231 (Additional file 1: Figure S2); however, the
cytotoxic activity of TPZ did not reach statistical signifi-
cance even at relatively high concentrations (20 μM)
under both normoxic and hypoxic conditions (Additional
file 1: Figure S2). This led us to drop further comparative
experiments between DCQ and TPZ.
DCQ induces apoptosis and DNA damage more significantly
under hypoxia
We then used IC50 concentrations of DCQ (3 μM in
MDA-MB-231; 5 μM in MCF-7) to investigate drug
effects on cell cycle by flow cytometric analysis of fluores-
cent PI-stained cellular DNA (Additional file 1: Figure S3).
Cells exposed to DCQ for 24 hours under normoxia or
hypoxia (6 hours in 1% oxygen followed by 18 hours in
normoxia) exhibited an increase in the pre G1 popu-
lation more significantly under hypoxia than normoxia
(Additional file 1: Figure S3). Since the accumulation of
cells in pre G1 may be due to apoptosis, TUNEL and
annexin V/PI assays were performed to confirm the























































































































































Figure 1 DCQ reduces the viability and colony forming ability of breast cancer cell lines (MDA-MB-231 and MCF-7). (A) MTT viability
assay was performed after 6 hours of exposure to DCQ under normoxia (21%) or hypoxia (1%). Results (Average ± SE) are from triplicate
measurements from 3 independent experiments. One-way ANOVA was used to compare DCQ-treated versus control and statistical significance of
p < 0.05 is indicated by *. Two sample t-test was used to compare between the effect of DCQ under normoxia versus hypoxia under the same
concentration, p < 0.05 is indicated by †. (B,C) Clonogenic survival assay of cells exposed to different concentrations of DCQ under normoxia or
hypoxia. Cells were treated with DCQ and incubated for 3 hours after which they were trypsinized and re-plated at a density of 300 cells/100 mm
petri dish and surviving colonies (>50 cells) were counted 12 days after plating. *p < 0.05 significance with respect to control (one way ANOVA).
†p < 0.05 significant difference between normoxia and hypoxia at the same DCQ concentration (two sample t-test). Results (Average ± SE) are
from duplicate measurements of 3 independent experiments.
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normoxia (28% vs 9% in MDA-MB-231; 21% vs 3% in
MCF-7) (Figure 2A). This enhanced apoptosis under hyp-
oxia was confirmed by Annexin V/PI assay (Figure 2B),
suggesting that the increases in pre G1 observed by flow
cytometry are due to apoptosis. Higher DCQ concentra-
tions of 5 μM caused more than 80% apoptosis in MDA-
MB-231 and loss of difference in drug efficacy between
normoxia and hypoxia. Consistent with viability and
colony formation assay, the p53 wild type MCF-7 cells
were more resistant to the pro-apoptotic effects of DCQ
(p < 0.05, Figure 2).We have shown that DCQ induces DNA damage and
the DNA damage response signaling pathway leading to
apoptosis [19,24]. To confirm that DCQ exerts its antitu-
mor effect in MCF-7 and MDA-231 by a similar mechan-
ism, we investigated changes in the levels of gamma-H2AX,
a marker of DNA damage [28]. Under hypoxic conditions,
5 μM DCQ elicited a marked increase in gamma-H2AX
protein in both cell lines (Figure 3A). We then investigated
whether DCQ-induced DNA damage activates p53 in
MCF-7 cells, as in human colon cancer cells [19]. No
changes in total p53 protein were observed; however, in ac-





































































































Figure 2 Differential sensitivity of MDA-MB-231 and MCF-7 to DCQ-induced apoptosis. (A) Cells were treated with DCQ for 6 hours under
normoxia or hypoxia. After 24 hours, the extent of DNA fragmentation was determined by TUNEL assay and measured by flow cytometry. (B) Cells
were treated with DCQ for 6 hours under normoxia or hypoxia. After 24 hours control and DCQ treated cells were stained with fluorescein-conjugated
annexin V and PI; apoptotic and necrotic cells were analyzed by flow cytometry. The percentage of apoptotic cells was determined in response to
DCQ using CellQuest software and the averages ± SE were obtained from the results of three independent experiments each done in duplicate. Two
sample t-test was used to compare between the effect of DCQ under normoxia versus hypoxia under the same concentration, p < 0.05 is indicated
by †. The effect of the same concentration of DCQ (3 μM and 5 μM) on the two cell lines was compared by t-test. MCF-7 cells were more resistant to
DCQ apoptotic effect than the MDA-MB-231 (p < 0.05).
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increased by DCQ, especially under hypoxia. Considering
that MDA-MB-231 cells harbor a p53 dominant-negative
mutation, there was no distinct band of p-p53 and no
changes in p53 protein expression were induced by DCQ
in this cell line (Figure 3A).
DCQ induces apoptosis via the generation of reactive oxygen
species
Quinoxaline dioxides are known to cause DNA damage
either via direct interaction with DNA or through the
induction of ROS [11,16,17]. To investigate whether
DNA damage by DCQ is associated with an increase in
intracellular ROS, we measured ROS by the dichlo-
rofluorescin assay in MCF-7 and MDA-MB-231 cells
exposed to DCQ under hypoxia (Figure 3B). An oxidant
shift was observed in MCF-7 and MDA-MB-231 cells
after 1 hour of treatment with DCQ, and the extent of
ROS production was greater in MDA-MB-231 (95%) in
comparison to MCF-7 (60%) cells, which may explain
the enhanced drug sensitivity of MDA-MB-231. A 2
hour pretreatment with the strong antioxidant vitamin E
or the reducing agent DTT suppressed DCQ-inducedROS levels by 40-100% in both cell lines (Figure 3B). In
addition, both antioxidants significantly protected breast
cancer cells against DCQ-induced apoptosis (Figure 3C).
The percentage of TUNEL positive cells decreased to
control levels upon pretreatment with vitamin E or DTT
(Figure 3C), suggesting that intracellular ROS play a role
in DCQ-induced apoptosis. HPLC and thin layer chro-
matography showed no direct drug interaction between
the antioxidants and DCQ (data not shown).
DCQ antitumor activity in MCF-7 and MDA-MB-231 is
through inhibition of HIF-1α via different mechanisms
We have shown that the hypoxia-induced cytotoxic
activity of DCQ is associated with the reduction of HIF-
1α accumulation [18,19,23,24]. However, the mechanism
by which DCQ suppresses HIF-1α is poorly understood.
In p53 wild type MCF-7 cells, HIF-1α band was only
detected under hypoxia and its expression was abrogated
in response to DCQ (Figure 3D). In MDA-MB-231 cells;
however, HIF-1α was constitutively expressed under
normoxia, and its expression was markedly increased
under hypoxia. The increase in HIF-1α protein in MDA-
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Figure 3 DCQ induces DNA damage and apoptosis via reactive oxygen species. (A) Whole cell lysates of MCF-7 and MDA-MB-231 were
prepared after 6 hours of exposure to DCQ (5 μM) under normoxia or hypoxia, and blots were probed for p-H2AX, p53, p-p53, p21, HIF-1α and
GAPDH. Results are representative of three independent experiments. (B) MDA-MB-231 and MCF-7 cells were pretreated with 1 mM Vitamin E or
DTT for 2 hours followed by 25 min incubation with 10 μM CM-H2DCFDA dye. Cells were washed with PBS and treated with DCQ for 1 hour
under normoxia or hypoxia, after which cells were harvested and the amount of DCF fluorescence was analyzed by flow cytometry. Each percentage
is the average ± SE of three independent experiments. (C) MDA-MB-231 and MCF-7 cells were pretreated with 1 mM Vitamin E or DTT for 2 hours
followed by 6 hours treatment with DCQ under normoxia or hypoxia. After 24 hours, the extent of DNA fragmentation was determined by TUNEL
assay and measured by flow cytometry. One-way ANOVA was used to compare DCQ-treated versus control and statistical significance of p < 0.05 is
indicated by *. (D) Whole cell lysates of MCF-7 and MDA-MB-231 were prepared after 6 hours of exposure to DCQ (5 μM) under normoxia or hypoxia,
and blots were probed for HIF-1α and GAPDH. Results are representative of three independent experiments.
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231 cells with DTT followed by DCQ under hypoxia.
Pretreatment with the reducing agent DTT did not
reverse the inhibitory effect of DCQ on HIF-1α protein,
suggesting a ROS independent mechanism of HIF-1α
regulation (Additional file 1: Figure S4).
It was shown that in MCF-7 cells, DNA damaging
agents activate p53, which in turn targets HIF-1α to
proteasomal-dependent degradation [28]. Having shown
that DCQ induces DNA damage in this cell line, we
assessed whether p53 plays a similar role in DCQ-induced
downregulation of HIF-1α. We hypothesized that, if the
activation of p53 by DCQ targets HIF-1α to degradation,then silencing p53 would reverse this effect and protect
against HIF-1α down regulation. To address this, MCF-7
cells were transfected with siRNA against p53 and the
levels of HIF-1α and p21 were assessed by western blot
(Figure 4A). Under hypoxia, DCQ caused a reduction in
HIF-1α protein in non-transfected and control MCF-7
cells. However, silencing p53 by siRNA did not completely
reverse the effect of DCQ on HIF-1α, suggesting that p53
is not the major mediator of DCQ-induced downregulation
of HIF-1α (Figure 4A). DCQ-induced down regulation of
p21 was also not affected by p53 silencing, indicating a
p53-independent mechanism for the decrease of p21 in
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Figure 4 DCQ reduces HIF-1α through different mechanisms in MCF-7 and MDA-MB-231. (A) MCF-7 cells were transfected with siRNA
against p53 and ctrl siRNA (scrambled sequence) using lipofectamine 2000. After 24 hours, cells were treated with DCQ (5 μM) for 6 hours under
hypoxia. Whole cell lysates were prepared, and blots were probed against indicated antibodies. (B) MCF-7 cells were transfected with siRNA
against p53 and ctrl siRNA (scrambled sequence) using lipofectamine 2000. Transfected cells were treated with DCQ (5 μM) for 6 hours under
hypoxia. The extent of DNA fragmentation was determined by TUNEL assay 24 hours later using flow cytometry. One-way ANOVA was used to
compare DCQ-treated versus control and statistical significance of p < 0.05 is indicated by *. (C) Whole cell lysates were prepared after pretreating
MCF-7 and MDA-MB-231 with the proteasome inhibitor MG132 (3 μM) then treated with DCQ, and blots were probed for HIF-1α. Results are from
three independent experiments. (D) Whole cell lysates of MCF-7 were prepared after 6 hours of exposure to DCQ (5 μM) under normoxia or
hypoxia, and blots were probed for p-AKT, mTOR, p-mTOR and GAPDH.
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induced apoptosis. Interestingly, DCQ increased the per-
centage of TUNEL positive cells under hypoxia from 5
to 23%, and this was not reduced upon silencing of p53
(25%), confirming that DCQ induces apoptosis in a p53-
independent manner (Figure 4B). We investigated whether
DCQ is targeting HIF-1α to proteasomal-dependent deg-
radation by pretreating MCF-7 and MDA-MB-231 with
the proteasome inhibitor MG132. As expected, in MCF-7,
DCQ reduced the levels of HIF-1α in an MG132-inde-
pendent manner (in line with p53 independent role),
indicating a proteasomal-independent down regulation of
HIF-1α (Figure 4C). However, in MDA-MB-231, DCQ
reduced HIF-1 α to control levels, and this was abrogated
by pretreatment of cells with MG132, suggesting that theproteasome is involved in DCQ-induced down regulation
of HIF-1α in this cell line (Figure 4C).
Since in MCF-7 cells the proteasome was not involved
in DCQ-induced HIF-1α inhibition, we investigated
whether other upstream regulators of HIF-1α translation
are responsible for this inhibition. It is known that the
activation of PI3-AKT-mTOR pathway shifts the balance
towards the accumulation of HIF-1α via increased trans-
lational activity [3]. Moreover, recent reports have shown
that TPZ down regulates HIF-1α by inhibiting its trans-
lation through enhanced phosphorylation of AKT and
reduction of mTOR phosphorylation [29]. In MCF-7
cells, we show that DCQ increases the phosphorylation
of AKT, and reduces the levels of phosphorylated mTOR,
suggesting that the downregulation of HIF-1α in this cell
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proteasomal degradation (Figure 4D).
DCQ significantly reduces hypoxia-induced TWIST, VEGF
secretion and migration
Hypoxia-induced increase in VEGF expression is con-
trolled by HIF-1α [3,10]. The levels of secreted VEGF were
examined by ELISA and were shown to be significantly
higher in supernatants of MCF-7 after exposure to hyp-
oxia for 12 hours, an effect that was completely reversed
by treating the cells with 2.5 μM DCQ (Figure 5A,B).
DCQ had no significant effect on VEGF secretion in
MDA-MB-231, possibly due to the fact that VEGF secre-
















































Figure 5 DCQ reduced HIF-1α downstream targets. (A, B) ELISA for sec
to DCQ under normoxia or hypoxia. Since 6 hours were insufficient to indu
treated with a lower concentration of DCQ for 12 hours. Results (Average ±
One-way ANOVA was used to compare DCQ-treated versus control and sta
were treated with DCQ (5 μM) for 6 hours either under normoxia or under
against TWIST. (D) Trans-well migration assay for cells after 24 hours of exp
seeded on top of matrigel apical insert in serum free media and the lower
treated with 2.5 μM DCQ or vehicle (supplemented in the upper chamber
the gel was fixed in 4% formaldehyde and cells were stained with Hoechst
obtained from the results of two independent experiments. One-way ANO
significance of p < 0.05 is indicated by *.Another target gene for HIF-1α involved in EMT is
TWIST. MDA-MBA-231 exhibit hypoxia-independent
elevated levels of TWIST, which is attributed to the high
basal levels of HIF-1α even under normoxia and is
thought to be responsible for the high invasive potential of
this cell line (Figure 3D) [12]. In line with the DCQ-
induced reduction in HIF-1α in MDA-MB-231, TWIST
levels were down regulated upon DCQ treatment under
normoxia and hypoxia (Figure 5B). Under the same con-
ditions, TWIST was undetectable by western blot in
MCF-7 cells.
Hypoxia enhances cell motility via several pathways in-
cluding HIF-1α [3]. To investigate whether the reduction



























Hypoxia _ +_ +_ _DCQ ++
C.
reted VEGF in MCF-7 cells and MDA-MB-231 after 12 hours of exposure
ce a difference in the secreted VEGF upon exposure to hypoxia, we
SE) are of duplicate measurements of two independent experiments.
tistical significance of p < 0.05 is indicated by *. (C) MDA-MB-231 cells
hypoxia. Whole cell lysates were prepared, and blots were probed
osure to DCQ under normoxia and hypoxia. 2 x 104 MCF-7 cells were
chamber (the will) was filled with 10% FBS media. Cells were either
only) under normoxia and hypoxia for 24 hours. Then the lower part of
and counted using fluorescence microscopy. The averages ± SE were
VA was used to compare DCQ-treated versus control and statistical
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MCF-7 and MDA-MB-231 cells over serum-reduced
matrigel for 24 hours under normoxia and hypoxia.
Incubation of cells under hypoxia for 6 hours was in-
sufficient to induce a change in the motility of MCF-
7 cells, however, 24 hours exposure to hypoxia led to
a 4-fold increase in the relative number of migrating MCF-
7 (Figure 5D) but not MDA-MB-231 (data not shown),
due to the hypoxia-independent migration ability of the
latter cell line [27]. Since 5 μM DCQ for 24 hours induced
significant cell death in MCF-7 cells, we studied the mo-
tility of this cell line in response to 2.5 μM DCQ and
showed significant reduction in hypoxia-induced cell mo-
tility (Figure 5D).
DCQ exhibits anti-metastatic activity in vivo
We validated the effect of DCQ in vivo using our estab-
lished experimental metastasis mouse model. Briefly,
4x106 MDA-MB-231 cells were injected s.d. into the
subcutaneous area of the neck region of NOD-SCID
mice. DCQ (17 mg/Kg in 50 μL DMSO) or DMSO
(50 μL as control) were administered i.p., twice per week
for 4 weeks, and tumor volume was monitored weekly.
Starting 3 weeks post treatment, tumor growth was
significantly reduced by DCQ (p < 0.0001) (Figure 6A).
Moreover, DCQ-treated mice showed significant improve-
ment in their overall survival (p < 0.01). Indeed, around
50% of DCQ-treated mice survived beyond 60 days, time
at which most DMSO-treated mice had already died
(Figure 6B).
We further studied if the effect of DCQ on survival
and tumor volume correlated with reduced metastasis to
the lungs and liver. Metastasis from the site of injection
(primary site) to the lungs and liver was studied by
histology at 5, 7 or 9 weeks post tumor cell injection
(Figure 6C). The infiltration of tumor cells was observed
in the lungs of untreated mice at 5 weeks, which in-
creased considerably at 7 weeks and reached its highest
level at 9 weeks (Figure 6C). On the other hand, no or
less infiltration was observed in the lungs of DCQ-
treated mice (Figure 6C). The liver, another common
secondary site of breast cancer metastasis, was also
examined for tumor infiltration. Liver metastases were
detected in DMSO-treated mice after 9 weeks; however,
no liver metastasis was observed in DCQ-treated mice
(Figure 6D). A marked difference in the lungs and livers
of drug treated mice compared to control mice was ob-
served at all time intervals (Figure 6C, D). Additionally,
immunohistochemistry of primary tumor tissue showed
that DCQ blocked the accumulation of HIF-1α (Figure 6E),
and significantly reduced the micro vessel density within
the primary tumor, as measured by anti-PECAM antibody
(Figure 6F). These data suggest that DCQ suppresses
metastasis in vivo and confirm the previously reportedanti-angiogenic activity of DCQ against mouse breast
tumors in vivo [23].
Discussion
Breast cancer is the most frequently diagnosed malignancy
in women. Heterogeneous distribution of hypoxic regions
is commonly detected within invasive breast tumors
[14,26]. These resistant regions are known to have larger
tumor sizes, and to consist of worse grade tumors that are
invasive and metastatic [25]. The use of hypoxia-activated
drugs is among the leading approaches to circumvent
hypoxia challenges [16]. This strategy provides selective
tumor suppression, thus offering minimal toxicity to non-
hypoxic tissues. Several hypoxia-activated compounds
have reached clinical trials for the treatment of a variety of
solid tumors [30-36]. However, so far these drugs have
shown moderate to low activity against breast cancer.
Here, we document for the first time that DCQ is a
hypoxia-activated cytotoxin effective against breast can-
cers that harbor different p53 status and have different in-
vasive potential. We show that DCQ induces apoptosis
and reduces HIF-1α regulated pathways. In human
breast cancer xenograft model, DCQ attenuated me-
tastasis to the lungs and liver and significantly reduced
tumor growth as compared to control mice (DMSO-
treated). Additionally, DCQ prolonged the survival of 50%
of treated mice beyond 60 days, by that time, however,
90% of untreated mice have already died. These data
suggest that targeting breast cancer with the hypoxia-
activated drug DCQ is a potential therapeutic approach to
suppress metastasis through the reduction of HIF-1α and
downstream activated pathways.
It has been shown that DCQ exerts its cytotoxic activ-
ity through different cellular mechanisms in a cell-type
specific manner [18-22]. In this study, DCQ was found
to reduce the viability and colony forming ability of MCF-
7 and MDA-MB-231 via the induction of apoptosis, an
effect that was significantly enhanced under hypoxia.
Interestingly, the p53 mutant and invasive MDA-MB-231
cell line was more sensitive to DCQ than p53 wild type
MCF-7 cells. In order to rule out the possible involvement
of p53 in drug sensitivity, we silenced functional p53 in
MCF-7 cells, and found that DCQ-induced apoptosis was
not enhanced, suggesting that the higher drug sensitivity
in MDA-MB-231, which provides additional selectivity for
tumor versus normal tissue toxicity, may not be attributed
to p53 status. This extends previous observations that
DCQ-induced apoptosis in HCT116 human colon cancer
cells is independent of p53 [19], rendering DCQ a promis-
ing molecule, especially when considering that more than
50% of human cancers bear mutated or abnormal p53.
Most hypoxia-activated drugs undergo bio-reductive
activation, which generates intra cellular reactive radi-




















































Figure 6 DCQ reduced tumor volume and metastasis and increases survival in vivo. In vivo model used to test the effect of DCQ, briefly
4 x 106 MDA-MB-231 were sub-dermally injected under the dorsal neck region of NOD-SCID mice. One week later mice were pooled into two
groups DCQ treated and control. (A) Effect of DCQ on tumor growth of sub-dermally injected MDA-MB-231 mice. The growth of the primary
tumor was monitored by measuring its dimensions on a weekly basis. Tumor volume (V, cm3) was determined by the equation: V = length ×
width × height). Data was plotted as the average tumor size of 2 separate experiments (10 mice/group/experiment) and error bars represent the
standard error of the means. One-way ANOVA was used to compare DCQ-treated versus control and statistical significance of p < 0.05 is indicated
by *. (B) Effect of DCQ on the survival of MDA-MB-231 injected mice. The survival curves of sub-dermally injected NOD-SCID mice by MDA-MB-231
cells, with DCQ treatment (17 mg/Kg in 50 μL DMSO) or control (in 50 μL DMSO). Experiment performed once with 22 mice per treatment group,
significant difference was tested by Log-Rank Mantel-Cox test, p value = 0.002. (C) H&E staining of the lung of s.d. injected MDA-MB-231 mice was
performed. Arrows indicate infiltration. (D) H&E staining of the liver samples of s.d. injected MDA-MB-231 mice was performed. Arrows indicate
infiltration. (E) Photograph of primary tumor from control and DCQ-treated mice with immunohistochemistry staining against HIF-1α after 5 weeks.
(F) Micro vessel density of cross section of primary tumors from control and DCQ-treated mice after 5 weeks. Results are from two mice per treatment
group. Average ± SE are plotted form blinded count low magnification.
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comet assay, we have previously demonstrated that
DCQ, when combined with radiotherapy, induces DNA
damage [19,22,24]. In accordance with these findings,
DCQ increased the levels of the DNA damage marker
gamma-H2AX in both breast cancer cell lines. Together
with previous findings [24], these data provide evidencethat DCQ is a potent DNA damaging agent under hyp-
oxic conditions.
ROS are known to mediate the DNA damaging effects
of hypoxia-activated prodrugs [17]. In our breast cancer
system, DCQ significantly increased the levels of intracel-
lular ROS under hypoxia after 1 hour of exposure. Inter-
estingly, a more pronounced increase of ROS generation
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(60%), which could explain the higher sensitivity of MDA-
MB-231 cells to DCQ. In fact, it has been documented
that MCF-7 cells are resistant to ROS-dependent apop-
tosis due to the high basal levels of NRF2, a transcription
factor involved in protective responses to oxidants, as well
as to elevated levels of intracellular glutathione [36]. In
both breast cancer cell lines, DCQ-mediated cell death
appears to require ROS production since drug toxicity
was reversed by the antioxidants vitamin E and DTT.
Almost 50% of breast cancer patients treated for local-
ized disease develop metastases [25]. Evidence suggests
that hypoxia contributes positively to breast tumor inva-
sion and metastasis [25,26]. Recent studies show that
hypoxia aids in the development or maintenance of breast
cancer stem cells [37,38]. HIF-1α is a major molecular
player by which hypoxia orchestrates such complex pat-
terns of gene expression in most solid tumors including
breast cancer [39-41]. Among other hypoxia-activated
prodrugs, DCQ-induced cell death was accompanied by a
reduction in the levels of HIF-1α in many cell lines
[18-22]. In MDA-MB-231 cells, DCQ reduces both basal
and hypoxia-induced accumulation of HIF-1α via protea-
somal degradation. In MCF-7 cells, it has been reported
that the activation of p53, by DNA damaging agents, tar-
gets HIF-1α to proteasome-dependent degradation [28].
Here we show that DCQ induces DNA damage in MCF-7
cells, however, unlike other DNA damaging agents, it does
not induce a proteasome-dependent degradation of
HIF-1α. Moreover, silencing p53 led to a non-significant
reversal of DCQ-induced down regulation of HIF-1α.
These data provide evidence that DCQ does not target
HIF-1α to degradation. Since, treating MCF-7 cells with
DCQ did not affect the mRNA transcript levels of HIF-1α
(data not shown), we suspected a possible anti-transla-
tional activity of DCQ. One of the major oncogenic path-
ways that shift the balance towards HIF-1α accumulation,
via increased translation, is the AKT/mTOR pathway
[8,42-44]. In fact, Zhan et al. reported that in Hela cells,
TPZ suppresses the translation of HIF-1α in an eIF2α
dependent manner [29]. This suppression was accompan-
ied by an increase in the levels of p-AKT (Ser 473) and a
reduction of p-mTOR (Ser 2448) [29]. Similar to TPZ,
DCQ induced an increase in the levels of p-AKT (Ser 473)
and a reduction of p-mTOR (Ser 2448), suggesting a
possible anti-translational activity in MCF-7 cells. Taken
together, we show that DCQ reduces HIF-1α in MDA-
MB-231 and MCF-7 cells via distinct mechanisms and
possibly independently of its DNA damaging effect
(Additional file 1: Figure S5).
HIF-1α is known to activate vital pathways involved in
metastasis [8]. In our breast cancer system, DCQ not
only reduced HIF-1α but also attenuated hypoxia-induced
invasion. The reversal of hypoxia induced VEGF secretionis in accordance with the anti-angiogenic effect of DCQ
documented earlier in mouse mammary epithelial cells in
C57BL mice [23]. HIF-1α plays a central role in metastasis
via direct regulation of several EMT regulators such as
Snail, SLUG, and TWIST [11-14]. Here we report that
targeting breast cancer cells with the hypoxia-activated
drug, DCQ, reduces hypoxia-induced EMT, as indicated
by the reduction of hypoxia-induced cell migration in
MCF-7 cells and downregulation of TWIST in MDA-MB-
231. In MDA-MB-231, the incomplete abrogation of HIF-
1α and TWIST possibly explains the limited effect of
DCQ on hypoxia-induced migration in this cell line [12].
In fact, exposure of MDA-MB-231 to hypoxia did not
significantly alter their behavior, which may be due to the
considerably high basal levels of HIF-1α in this cell line or
to the constitutive activation of several oncogenic path-
ways involved in angiogenesis and EMT in these cells
[12,13,25,45].
The present study shows that the hypoxia-activated
drug, DCQ, is more effective than the clinically used drug
tirapazamine (TPZ) against breast cancer cell lines. DCQ
induces ROS-dependent, p53-independent apoptosis in
breast cancer cell lines in vitro. Additionally, DCQ reduces
primary tumor volume, reduces secondary site invasion,
and significantly increases survival in vivo. DCQ exhibits
its unique pro-apoptotic and anti-metastatic properties
via the reduction of HIF-1α and downstream signaling
cascades.
Conclusions
Despite the involvement of hypoxia in breast cancer pro-
gression, no hypoxia-activated drug has been shown to
be effective against breast tumors so far. Here, we show
that targeting breast cancers with the hypoxia-activated
drug, DCQ, induces ROS-dependent apoptosis in vitro,
inhibits primary tumor volume, reduces secondary site in-
vasion, and significantly increases survival in vivo. DCQ
exhibits its unique pro-apoptotic and anti-metastatic
properties via the reduction of HIF-1α and downstream
signaling cascades. Additionally, DCQ is more effective
than the clinically used drug tirapazamine (TPZ) against




DCQ was synthesized from 5,6-dichlorobenzofurazan
oxide and dibenzoylmethane via the Beirut Reaction [46].
RPMI 1640, 10X trypsin-EDTA, 0.25X trypsin-EDTA,
Dulbecco’s Phosphate Buffered Saline (PBS), Fetal Bovine
Serum (FBS), sodium bicarbonate, penicillin-streptomycin
(P/S), DMSO, trypan blue, vitamin E, and Dithiothreitol
(DTT) were purchased from Sigma, St. Louis, MO, USA.
Propidium iodide (PI) and CM-H2DCFDA were purchased
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Protease Inhibitor MG-132 was purchased from Roche
Applied Science, Penzberg, Germany.
Cell lines and cell culture
The human breast cell lines MCF-7 (p53 wildtype, nonin-
vasive [27]), MDA-MB-231 (p53 mutant, invasive, [27])
and MCF-10A (p53 wildtype, immortalized normal breast
[27]) were originally obtained from ATCC and were con-
stantly tested for mycoplasma contamination. No authen-
tication was performed by the authors. Cells were grown
in RPMI 1640 modified medium supplemented with 10%
heat-inactivated FBS and 1% Pen-Strep. All cells were
maintained in a humidified atmosphere of 5% CO2 and
95% air. DCQ (7.5 mg) was dissolved in 1 ml of DMSO
then diluted in media (DMSO ≤ 0.1%). For hypoxia expos-
ure, cells were placed in a tightly sealed chamber (Bactron
III, SHEL LAB, UK) at 37°C. The desired oxygen level was
monitored by an Ohmeda Oxymeter and maintained by
pumping a gas mixture of 1% O2, 5% CO2, and 94% N2,
unless otherwise mentioned.
Viability and clonogenic survival
Cells (104) were treated with drugs 24 hours after plating.
Cell viability was tested 6 hours or 24 hours after treatment
by the non-radioactive cell proliferation kit (Promega
Corporation, Madison, USA), an MTT-based method. Clo-
nogenic survival was performed as described previously
[19]. Briefly, cells were treated with DCQ for 3 hours under
normoxia (21% O2) or hypoxia (1%, 10% O2), trypsinized,
then re-plated at a density of 300 living cells/100 mm petri
dish without the drug. 12 days later, cells were stained with
aqueous 0.5% solution of crystal violet and the number of
colonies having more than 50 cells was recorded.
Flow cytometric analysis
Flow cytometric analysis was performed as previously
described [24]. Briefly, cells were treated with DCQ at
50% confluency, and incubated for 6 hours under nor-
moxia or hypoxia and the PI-stained DNA content was
measured using Fluorescence Activated Cell Sorter (FACS)
flow cytometer (Becton Dickinson, Research Triangle, NC).
For Annexin V/PI, after treatment, cell pellets were washed
with PBS and re-suspended in 100 μl Annexin-V-Fluos
labeling solution (20 μl annexin reagent and 20 μl PI
(50 μg/ml) in 1000 μl incubation buffer pH 7.4 (10 mM
Hepes/NaOH, 140 mM NaCl, 5 mM CaCl2). Samples
were incubated for 15 mins at room temperature and
0.5 ml incubation buffer was added. Cellular fluorescence
was then measured by flow FACS.
Western blot and VEGF measurement
Western blots were performed as described earlier [19].
Membranes were probed with the primary antibodies:p21 ((C-19)-G), p53 (DO-1), p-p53, HIF-1α (Novus
Biologicals, Littleton, USA), gamma-H2AX, TWIST and
GAPDH followed by horseradish peroxidase-conjugated
anti-mouse, anti-rabbit, or anti-goat IgG-HRP (Santa-Cruz,
California, USA). All blots have been generated from
triplicate experiments after 6 hours of exposure to DCQ or
hypoxia. The concentration of VEGF in the culture super-
natant was measured using a quantitative sandwich enzyme
immunoassay (R&D Systems Inc., Minneapolis, USA) ac-
cording to the manufacturer’s instructions. VEGF concen-
trations were calculated by comparison with a standard
curve generated using a 4-parameter logistic curve-fit and
on-board software. VEGF concentrations were normalized
to amount (pg) per 1 × 106 living cells/10 ml supernatant.
Detection of ROS
At 50% confluency, cells were incubated with 10 μM of
CM-H2DCFDA in media (2% FBS) for 25 mins at 37ºC.
After which, cells were washed with PBS and treated
with 5 μM DCQ for 1 hour under hypoxia. Control and
treated cells were trypsinized, centrifuged, washed with
PBS, and fluorescence was immediately evaluated by
FACS. For the antioxidant experiments, cells were pre-
treated with 1 mM vitamin E or DTT for 2 hours, washed
with PBS, incubated with CM-H2DCFDA for 25 mins,
and the above protocol was performed to determine the
levels of ROS generated.
Trans-well migration assay
2 × 104 cells were seeded on top of reduced matrigel, in
the trans-well upper chamber, in serum free media and
the lower chamber was filled with 10% FBS media. Cells
were either treated with 2.5 μM DCQ (5 μM of DCQ is
toxic after 24 hours) or vehicle (supplemented in the
upper chamber only) under normoxia and hypoxia for 24
hours. Then the lower side of the trans-well membrane
was fixed in 4% formaldehyde and cells were stained with
Hoechst and counted using fluorescence microscopy.
Small interfering RNA (siRNA) transfections
siRNAs were used to knockdown p53 gene expression.
siRNA p53 (p53 siRNA (h): sc-29435), control si RNA
(Control siRNA-A: sc-37007) were purchased from Santa
Cruz, California, USA. The siRNAs were transfected into
MCF-7 cells using lipofectamine 2000 transfection reagent
(Invitrogen, New York, USA) following manufacturer’s
instructions. After 24 hours, cells were treated with DCQ
placed under hypoxia for 6 hours, and proteins were
extracted for western blot analysis.
Xenograft mouse model and histological assessment
This study was approved by the Institutional Animal Care
and Utilization Committee (IACUC) of the American
University of Beirut. Eight weeks aged female NOD-SCID
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(s.d.) with 4 × 106 MDA-MB-231 cells into the subcuta-
neous area of the neck region, in incomplete media. Treat-
ment groups included DCQ (17 mg/Kg in 50 μL DMSO)
or DMSO (50 μL) as control, which were administered
intraperitoneally (i.p.), twice per week for 4 weeks. Tox-
icity studies have shown that 17 mg/Kg in 50 μL DMSO is
a tolerated dose based on mice behavior and body weight.
The weight of animals was determined daily, and the date
of death was recorded. Survival curves were plotted using
Kaplan-Meier method. Tumor growth and progression
were monitored weekly by measurement of tumor size
(length, width, height) with a caliper device. These data
were plotted as the average tumor size of 22 mice/treat-
ment group. For histological assessment, at the indicated
time points (week 5, 7, and 9), 3 mice were anesthetized
with isofurane and sacrificed by cervical dislocation. Biop-
sies from lungs, liver, and primary tumor sites were ob-
tained. Tissues were sectioned at 6 μm thickness using a
paraffin microtome and mounted on slides and stained by
H&E or probed against HIF-1α or PECAM and were
examined by light microscopy. Three tumors (week 5) per
treatment group (DMSO versus DCQ) were assayed
for lumen containing micro-vessels. Micro-vessels were
counted from four random fields at low magnification.
Additional file
Additional file 1: Figure S1. DCQ spares normal breast cell lines under
normoxia. MTT viability assay was performed after 6 hours of exposure to
DCQ under normoxia (21%). Results (Average ± SE) are from triplicate
measurements from 3 independent experiments. Figure S2. DCQ
reduced viability of breast cancer cell lines more efficiently than TPZ.
Trypan blue exclusion assay was performed on MDA-MB-231 and MCF-7
cells exposed to DCQ and TPZ. 15 x 104 cells were seeded in 6 well
plates, 24 hours later, cells were treated with the indicated concentrations
of TPZ for 6 hours under normoxia (21% O2) or hypoxia (1% O2), and
were harvested 24 hours post treatment for MTT and trypan blue assays.
Results are of triplicate experiments. Figure S3. DCQ induces apoptosis
in breast cancer cell lines, preferentially under hypoxia. Cell cycle analysis
was performed on cells exposed to DCQ (IC50) for 6 hours under normoxia
or hypoxia and DNA content of PI stained cells was determined 24 hours
later. The percentage of PreG1 was determined using CellQuest software
and the averages ± SD were obtained from the results of at least two
independent experiments each done in duplicate. Figure S4. DCQ reduces
HIF-1α in MDA-MB-231 in a ROS-independent mechanism. MDA-MB-231
were pretreated with DTT for two hours, washed with PBS, then treated
with DCQ (5 μM). Whole cell lysates of MCF-7 were prepared after 6 hours
of exposure to DCQ under hypoxia, and blots were probed for HIF-1α and
GAPDH. Figure S5. DCQ reduces HIF-1α in MDA-MB-231 and MCF-7
via distinct mechanisms. In MCF-7 cells, DCQ inhibits the accumulation of
HIF-1α by reducing its synthesis, however, in MDA-MB-231 DCQ induces
proteasomal degradation of the protein. In both cell lines DCQ enhances
p-H2AX expression, and induces ROS-dependent apoptosis.
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